Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis

Yamada, Yasutaka; Nishikawa, Rika; Kato, Mayuko; Okato, Atsushi; Aoki, Takayuki; Kojima, Satoko; Yamazaki, Kazuto; Naya, Yukio; Ichikawa, Tomohiko; Seki, Naohiko

doi:10.1038/s10038-017-0371-1

Cited by 55 publications

(76 citation statements)

References 45 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We used 2 human RCC cell lines (786‐O and A498) obtained from ATCC (Manassas, VA, USA) as previously described . These cell lines were maintained in RPMI‐1640 with 10% FBS (HyClone, Logan, UT, USA).…”

Section: Methodsmentioning

confidence: 99%

“…Total RNA was extracted from human tissues and cell lines using TRIzol reagent (Invitrogen) according to the manufacturer's protocol, as we described previously . The procedure for PCR quantification has been outlined.…”

Section: Methodsmentioning

confidence: 99%

“…To identify miR‐451a target genes, we used in silico analyses and genome‐wide gene expression analyses, as outlined previously . We used the TargetScanHuman 7.0 (August 2015 release) (http://www.targetscan.org/), TCGA, and OncoLnc datasets (http://www.oncolnc.org/) to select and narrow down putative miRNA target genes .…”

Section: Methodsmentioning

confidence: 99%

“…Anti‐GAPDH antibodies (1:10 000, ab8245; Abcam) were used as an internal loading control. The procedures have been described …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

Recent analyses of our microRNA (miRNA) expression signatures obtained from several types of cancer have provided novel information on their molecular pathology. In renal cell carcinoma (RCC), expression of microRNA‐451a (miR‐451a) was significantly downregulated in patient specimens and low expression of miR‐451a was significantly associated with poor prognosis of RCC patients (P = .00305) based on data in The Cancer Genome Atlas. The aims of the present study were to investigate the antitumor roles of miR‐451a and to identify novel oncogenic networks it regulated in RCC cells. Ectopic expression of miR‐451a significantly inhibited cancer cell migration and invasion by RCC cell lines, suggesting that miR‐451a had antitumor roles. To identify oncogenes regulated by miR‐451a in RCC cells, we analyzed genome‐wide gene expression data and examined information in in silico databases. A total of 16 oncogenes and were found to be possible targets of miR‐451a regulation. Interestingly, high expression of 9 genes (PMM2,CRELD2,CLEC2D,SPC25,BST2,EVL,TBX15,DPYSL3, and NAMPT) was significantly associated with poor prognosis. In this study, we focused on phosphomannomutase 2 (PMM2), which was the most strongly associated with prognosis. Overexpression of PMM2 was detected in clinical specimens and Spearman's rank test indicated a negative correlation between the expression levels of miR‐451a and PMM2 (P = .0409). Knockdown of PMM2 in RCC cells inhibited cancer cell migration and invasion, indicating overexpression of PMM2 could promote malignancy. Analytic strategies based on antitumor miRNAs is an effective tool for identification of novel pathways of cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Anti‐GAPDH antibodies (1:10 000, ab8245; Abcam) were used as an internal loading control. The procedures have been described …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Initial study on HMGB3 revealed that it participated in regulating the balance between self-renewal and differentiation in hematopoietic stem cells (11). The oncogenic potential and prognostic value of HMGB3 in different cancer types has also been appreciated (34,35).…”

Section: Discussionmentioning

confidence: 99%

Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non‑small cell lung cancer cells

Song

Wang

Feng³

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Previous research has linked high mobility group box 3 (HMGB3) overexpression to the malignant progression and poor prognosis of non-small cell lung cancer (NSCLC). The present study investigated the role of HMGB3 in cell survival and colony formation of NSCLC cells. Stable knockdown of HMGB3 in A549 cells was achieved by lentiviral-based shRNA interference and verified by detection of the transcriptional and translational level of HMGB3 with reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. The influence of HMGB3 knockdown on A549 cell viability and apoptotic rate was evaluated by Cell Counting Kit-8 assay and flow cytometry following annexin V staining, respectively. The proliferative capacity of A549 cells with or without HMGB3 knockdown was compared by measuring their colony forming efficiency. The results of the current study revealed that HMGB3 knockdown significantly reduced cell viability and colony forming efficiency while promoting apoptosis in A549 cells, indicating that HMGB3 may be pivotal for the survival and colony formation of A549 cells, serving a notable role in NSCLC progression.

show abstract

Pirin: a potential novel therapeutic target for castration‐resistant prostate cancer regulated by miR‐455‐5p

et al. 2018

Self Cite

View full text Add to dashboard Cite

Androgen deprivation therapy is frequently used to treat prostate cancer (PCa), but resistance can occur, a condition known as castration‐resistant prostate cancer (CRPC). Thus, novel approaches for identification of CRPC are important for designing effective PCa treatments. Analysis of microRNA (miRNA) expression signatures by RNA sequencing showed that both passenger and guide strands of the miR‐455‐duplex (miR‐455‐5p and miR‐455‐3p, respectively) acted as antitumor miRNAs in PCa cells. The involvement of miRNA passenger strands in cancer pathogenesis is a novel concept for miRNA functionality. Based on a large patient cohort in The Cancer Genome Atlas, expression of eight miR‐455‐5p/‐3p target genes (PIR: P = 0.0137, LRP8: P = 0.0495, IGFBP3: P = 0.0172, DMBX1: P = 0.0175, CCDC64: P = 0.0446, TUBB1: P = 0.0149, KIF21B: P = 0.0336, and NFAM1: P = 0.0013) was significantly associated with poor prognosis of PCa patients. Here, we focused on PIR (pirin), a highly conserved member of the cupin superfamily. PIR expression was directly regulated by miR‐455‐5p, and PIR overexpression was detected in hormone‐sensitive prostate cancer (HSPC) surgical specimens and CRPC autopsy specimens. Loss‐of‐function assays using siRNA or an inhibitor (bisamide) showed that downregulation of PIR expression blocked cancer cell migration and invasion. Moreover, the miR‐455‐5p/PIR axis contributed to cancer cell aggressiveness. These results suggest that PIR might be a promising diagnostic marker for HSPC and CRPC. Furthermore, CRPC treatment strategies targeting PIR may be possible in the future. Identification of antitumor miRNAs, including miRNA passenger strands, may contribute to the development of new diagnostic markers and therapeutic strategies for CRPC.

show abstract

Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis

Cited by 55 publications

References 45 publications

Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma

Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma

Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non‑small cell lung cancer cells

Pirin: a potential novel therapeutic target for castration‐resistant prostate cancer regulated by miR‐455‐5p

Contact Info

Product

Resources

About